1H17 Results

21 July 2017

This document has been prepared by NATURHOUSE HEALTH S.A. ("NATURHOUSE" or the "Company") for its exclusive use during the presentations announcing the Company's results of 1H17. NATURHOUSE does not authorise its dissemination, publication or use by any other person, whether physical or legal, to an end other than that which has been expressed above, unless they have prior express consent in writing from NATURHOUSE, and neither does it, consequently, accept any responsibility for the content of the document if it is used to an end other than that expressed above without the authorisation of the Company.

Readers are warned that the information in this document has not been audited by the Company's auditors and it has been summarised. The information and the opinions and statements contained in this document have not been verified by independent third parties and, unless another source is expressly mentioned, they have been drawn up by the Company.

This document contains forecasts and estimates relating to the business progress or results of the Company in the future. These forecasts respond to the current opinion and expectations of NATURHOUSE HEALTH, S.A. These forecasts, that are uncertain by nature, are affected by risks, including those mentioned in the prospectus for the IPO and the offering and listing of NATURHOUSE shares, approved by the CNMV (Spanish stock exchange commission) and recorded in its official register on 9 April 2015, and it is available to investors on the issuer's website (www.naturhouse.com) and that of the CNMV (www.cnmv.es). These risks may cause real results to be significantly different to said forecasts or estimates.

The contents of this document must be taken into account by all individuals or entities that may have to make decisions or draw up or disseminate opinions regarding shares issued by NATURHOUSE HEALTH SA, and in particular by the analysts that make use of this document.

This document is not an offer of sale or subscription and neither is it an invitation to subscribe to or acquire NATURHOUSE shares or any other securities in Spain or in any other jurisdiction.

2

  • Main Figures
  • Consolidated Profit & Loss Account
  • Sales and EBITDA by Country
  • Naturhouse Centres
  • Net Cash & Dividends
  • Consolidated Balance Sheet
  • Strategy & Outlook
  • Price Sensitive Information Notes for the Period

3

The Board of Directors has agreed to pay an interim dividend for 2017 of €0.20/share, to be paid on 15 September, which brings per-dividend

yield (based on the price at the end of June) to 4.7%*.

"+74 net openings in 2017, achieving 61% of the guidance for 2017" "France speeds up its growth in 2Q17 to 3.3% vs 0.6% in 1Q17 and Spain continues to provide positive results, leading us to think that it will return to growth in the coming quarters" "EBITDA margin of 35.2%, higher than the forecast range for 2017 (30%-35%), in spite of the costs from developing new markets and increased spending on staff" "Net cash position stands at €16.5m, after paying out €10.8m in dividends in May. This amount is a 28% increase vs end 2016, and shows that the company's cash generation capacity remains considerable" 1H16 1H17 %

Sales

54,503

54,288

-0.4%

EBITDA

19,931

19,108

-4.1%

EBITDA Margin

36.6%

35.2%

Net Income

13,920

13,441

-3.4%

Centres

2,279

2,353

74

Countries

32

32

-

Net Cash Position

12,814 **

16,483

28.6%

In Thousand of euros

*Calculated according to Naturhouse's closing price on 30 June 2017 (€4.25/share). 4

** As of end 2016

Naturhouse Health SA published this content on 21 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 July 2017 17:04:00 UTC.

Original documenthttp://www.naturhouse.com/wp-content/uploads/2017/07/1H17-Results-presentation.pdf

Public permalinkhttp://www.publicnow.com/view/88749154AB29C9F7677A59FDEED7C8DE2D7813DE